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RNA activation of haploinsufficient 
Foxg1 gene in murine neocortex
Cristina Fimiani1,*, Elisa Goina1,*,†, Qin Su2, Guangping Gao2,3,4 & Antonello Mallamaci1
More than one hundred distinct gene hemizygosities are specifically linked to epilepsy, mental 
retardation, autism, schizophrenia and neuro-degeneration. Radical repair of these gene deficits via 
genome engineering is hardly feasible. The same applies to therapeutic stimulation of the spared allele 
by artificial transactivators. Small activating RNAs (saRNAs) offer an alternative, appealing approach. As 
a proof-of-principle, here we tested this approach on the Rett syndrome-linked, haploinsufficient, Foxg1 
brain patterning gene. We selected a set of artificial small activating RNAs (saRNAs) upregulating it in 
neocortical precursors and their derivatives. Expression of these effectors achieved a robust biological 
outcome. saRNA-driven activation (RNAa) was limited to neural cells which normally express Foxg1 and 
did not hide endogenous gene tuning. saRNAs recognized target chromatin through a ncRNA stemming 
from it. Gene upregulation required Ago1 and was associated to RNApolII enrichment throughout the 
Foxg1 locus. Finally, saRNA delivery to murine neonatal brain replicated Foxg1-RNAa in vivo.
More than one hundred different hemizygous gene deletions underlie a variety of neuropathological conditions, 
leading to epilepsy, mental retardation, autism, schizophrenia and neurodegeneration1–5. Their individual prev-
alence is low, however their cumulative frequency makes them an issue for social health. A scalable therapeutic 
approach is needed.
How to achieve this goal? In principle, homologous recombination (HR)-mediated repair of defective genes, 
triggered by Engineered EndoNucleases (EEN) and driven by a dedicated editor DNA, should be the golden 
procedure to fix the problem6–8. In reality, the implementation of this approach within the CNS would be hardly 
feasible, due to a variety of technical issues9–11. A more spartan design, based on therapeutic minigenes, would 
be problematic as well. In fact, the exact rescue of gene expression levels is often needed for proper execution of 
neural gene functions12–14. Moreover, the faithful recapitulation of the gene expression pattern generally requires 
a number of properly arranged cis-active elements. Clustering all of them into a small transgene, suitable for 
panneural delivery, can be hardly feasible and/or scalable. Therefore, a different approach is needed. This might 
be a gentle stimulation of the spared gene allele, still under the control of the regulatory elements which shape its 
baseline expression profile and mediate subtle modulation of its levels linked to neuronal physiology.
Nowadays, two classes of molecular tools are potentially available for this last approach: (a) artificial tran-
scription factors, and (b) small activating RNAs (saRNAs). The former ones include Zinc finger- (ZF-)15–19, 
TransActivator Like Element- (TALE-)20–22, Clustered Regularly Interspaced Short Palindromic Repeat 
(CRISPR)-23–28 and NMHV-type29 transactivators. Despite their capability to stimulate endogenous genes ad libi-
tum, their employment for therapy of neural haploinsufficiencies may be problematic, because of their very large 
size30 and ectopic gene activation26–28,31. saRNAs, i.e. miRNA/siRNA-like molecules targeting the surroundings of 
the transcription unit in order, may also stimulate transcription, upon delivery as mature moieties, pri-miRNA- 
or shRNA precursors. As such, they work as effectors of “RNA(-dependent gene) activation” (RNAa)32–34. After 
the initial RNAa report by Li et al.35, several genes were transactivated by saRNAs32–34. Despite the intricate and 
heterogenous epigenetic changes evoked by these effectors36, their ultimate functional outcome seems to be basi-
cally attributable to two distinct molecular mechanisms. saRNAs can act by destabilizing ncRNAs which normally 
dampen mRNA transcritpion. Alternatively, they can convey the transcriptional machinery to chromatin37,38. 
Interestingly, moderate power and small size of saRNAs make them a promising tool for treatment of neural 
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haploinsufficiencies. However their biological effectiveness, selectivity and compliance with endogenous gene 
tuning still wait for in depth characterization.
As a proof-of-principle, here we employed RNAa to stimulate the haploinsufficient Foxg1 transcription factor 
gene. Foxg1 is a key regulator of cortico-cerebral development and function, implicated in pallial field specifica-
tion39, precursors proliferation control40,41 and laminar42 as well as areal43 neuronal differentiation. In humans, its 
allele dosage is crucial to neurological health, as hemideletion and duplication of Foxg1 lead to Rett and West syn-
dromes, respectively44. Briefly, we found that RNAa resulted into a Foxg1 expression gain suitable for therapeutic 
purposes and led to an appreciable biological outcome. No ectopic gene activation occurred and endogenous gene 
tuning was preserved. Finally, a robust Foxg1 stimulation was also achieved in vivo.
Results
Selecting miRNA-like saRNAs upregulating Foxg1-mRNA. In order to identify potential genomic 
targets appropriate for Foxg1-RNAa, we inspected the 5′ surroundings of NCBI-RefSeq Foxg1-mRNA transcrip-
tional start sites (TSSs) for sequences specifically amenable to miRNA targeting, via the pri-miRNA-155-based 
Block-It platform45. We selected eight high-score candidates (Fig. 1A and Supplementary Table 1) and we cloned 
the cDNAs, encoding for the corresponding precursors, into the lentiviral constitutive expressor pLVmiR.2345 
(Fig. 1B,(a)). We acutely delivered the resulting lentiviruses to murine E12.5 neocortical precursors, we kept these 
cells as floating neurospheres in pro-proliferative medium for four days and we eventually scored them for Foxg1-
mRNA levels by qRTPCR (Fig. 1C). We found that 8 out of 8 miRNAs, 4 antisense-oriented (miR-α Foxg1.0650, 
miR-α Foxg1.1653, miR-α Foxg1.2764 and miR-α Foxg1.3700) and 4 sense-oriented (miR-α Foxg1.0755, miR-α 
Foxg1.1694, miR-α Foxg1.2273 and miR-α Foxg1.3795), upregulated Foxg1, to different extents. The expression 
gain ranged from 1.28 ± 0.24-folds (miR-α Foxg1.2764) to 2.88 ± 0.34-folds (miR-α Foxg1.0650) (Fig. 1E and 
Supplementary Table 2). Similar results were achieved upon delivery of miR-α Foxg1.0650 and miR-α Foxg1.1694 
to NIH3T3 and HEK293T cells, which led to a consistent increase of Foxg1/FOXG1 proteins (Fig. S1 and 
Supplementary Table 2).
Next, we wondered if Foxg1-RNAa may be also achieved in differentiating derivatives of neocortical pre-
cursors. We transferred the pri-miRNA-cDNAs of the four best-performing miRNAs (Fig. 1E) into LV_
TREt-IRES2EGFP46, inbetween the doxycyclin-controlled TREt promoter and an IRES2EGFP reporter gene 
(Fig. 1B,(b2)). We employed the resulting lentiviruses - paired to a constitutive rtTA2S-M2 transactivator expres-
sor, LV_Pgk1p-rtTA2S-M246 (Fig. 1B,(b1)), to drive delayed, TetON-controlled miRNA expression. Unexpectedly, 
we found that only one miRNA (miR-α Foxg1.1694) upregulated Foxg1, by 1.56 ± 0.11-folds. The other ones were 
uneffective (Fig. 1F and Supplementary Table 2).
Finally, to corroborate the significance of these results, we tested if the small expression gain elicited by our 
saRNAs led to an appreciable biological readout. For this purpose, we stimulated Foxg1 by miR-α Foxg1.0650 and 
.1694 in proliferating murine neocortical precursors (Fig. 2A,B) and we evaluated the impact of this manipulation 
on the generation of postmitotic, Tubβ 3+ neurons. Foxg1 - in fact - inhibits the exit of neuronogenic precursors 
from cell cycle40,41 and even a small increase of its expression level is known to exert a deep impact on neuron-
ogenic differentiation rates29. As expected, both miRNAs halved the neuronal output of the culture, in a highly 
reproducible fashion (Fig. 2C,D and Supplementary Table 2).
Compliance of RNAa with endogenous tuning of Foxg1-mRNA. The therapeutic exploitation 
of RNAa for the treatment of haplo-insufficiencies would be easier if the activity of saRNAs would be con-
fined to cells normally expressing the gene in order. To assess the fulfilment of this requirement, we deliv-
ered miR-α Foxg1.0650 and .1694 to proliferating neural precursors originating from the murine E10.5 
meso-rhombo-cervical neural domain, which does not express Foxg147. We employed neural precursors dis-
sected out of the E12.5 neocortex as histogenetically-equivalent positive controls (Fig. 3A). Interestingly, albeit 
weakly upregulated by miR-α Foxg1.0650 and .1694, Foxg1 levels remained about 3 orders of magnitude lower in 
meso-rhombo-cervical derivatives, compared to neocortical controls (Fig. 3B,C and Supplementary Table 2). This 
suggests that risks of ectopic gene activation upon RNAa can be negligible.
Neuronal genes often undergo fine, electrical activity-related tuning, which may be crucial to proper imple-
mentation of their function48. An acceptable therapy of neuropathogenic haploinsufficiencies relying on stim-
ulation of the spared gene allele should take into account such physiological gene modulation. Exposure of 
neocortical neurons to high extracellular [K+] was followed by a prompt arousal of Foxg1-mRNA levels (Fig. 3D,E 
and Supplementary Table 2), a likely in vitro correlate of activity-dependent Foxg1 stimulation. We reasoned that 
this phenomenon might provide a valuable opportunity for probing compliance of RNAa with “endogenous” gene 
tuning. Remarkably, the delivery of miR-α Foxg1.1694 to K+-challenged neocortical neurons elicited a delicate 
upward shift of the Foxg1 activation curve under high extracellular [K+]. However, ANCOVA analysis of data 
provided no evidences of interaction between K+ stimulation and RNAa (Fig. 3E), suggesting that RNAa does not 
hide activity-driven Foxg1 tuning.
Molecular mechanisms underlying Foxg1-RNAa. RNAa is supposed to be a heterogeneous process 
and at least two classes of molecular mechanisms are supposed to underlie it. RNAa may take place via downreg-
ulation of ncRNAs which limit transcription of the associated gene of interest. Alternatively, saRNAs may drive 
molecular machinery promoting transcription to target chromatin37,38. To cast light on this issue, we monitored 
expression levels of the Foxg1-associated, sense-oriented AK158887 ncRNA (Fig. 4A), following the delivery 
of antisense-oriented, miR-α Foxg1.0650 and miR-α Foxg1.1653. No down-regulation of AK158887 was found, 
suggesting that, at least in these cases, the latter mechanism may apply (Fig. S2).
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As for recognition of target chromatin, saRNAs might straightly bind to unwound chromosomal 
DNA. Alternatively, they might pair to nascent RNA molecules stemming from it. To distinguish 
between these possibilities, we downregulated the putative miR-α Foxg1.0650 target AK158887 RNA, by 
gapmer-α AK158887-1.1 in easily transfectable NIH/3T3 cells Fig. 4A,B). Interestingly, such manipulation 
fully abolished miR-α Foxg1.0650-dependent Foxg1 transactivation (Fig. 4B), while not affecting Foxg1 levels in 
miRNA-NC-treated samples. This suggests that miR-α Foxg1.0650 recognizes its chromatin target via RNA/RNA 
pairing.
Both Ago1 and Ago2 are detectable in the nucleus and can bind miRNAs49. Ago2 was also specifically 
implicated in a number of RNAa cases, possibly acting as a bridge between the saRNA and the supramolecu-
lar transactivating complex50. To assess the involvement of Ago2 in Foxg1-RNAa, we evaluated its recruitment 
to miR-α Foxg1.0650 and .1694 target sequences, upon saRNA delivery to neocortical precursors, by ChIP. 
Enrichment for Ago1 was monitored as a specificity control. Unexpectedly, both saRNAs increased the recruit-
ment of Ago1, but not of Ago2 (Fig. 4C,D), pointing to a selective involvement of the former in Foxg1-RNAa. 
To corroborate this inference, we antagonized Ago1 translation by a dedicated morpholino in NIH/3T3 cells 
(Fig. 4E). Remarkably, this treatment suppressed miR-α Foxg1.1694-dependent Foxg1 transactivation (Fig. 4E), 
Figure 1. Screening for miRNA-like, small RNAs activating Foxg1-mRNA (Foxg1-saRNAs) in murine 
neocortical precursors and derivatives. (A) Schematics of the Foxg1 locus including saRNA positions and 
orientations as well as the diagnostic qRTPCR amplicon. (B–D) Lentiviral reagents and protocols employed 
for this screening. (E,F) Foxg1-mRNA levels in proliferating neocortical precursors and their differentiating 
derivatives, manipulated as in (C) and (D), respectively. Values double normalized, against Gapdh and control 
(NC). E, embryonic day. DIV, days in vitro. Bars represent sem’s. n = number of biological replicates. p-values  
were calculated by the t-Student algoritm (one-tail, unpaired). All results with p < 0.05 further passed 
Benjamini-Hochberg filtering, with FDR < 1/m.
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while not affecting Foxg1 levels in miRNA-NC-treated samples. All this confirms the pivotal role of Ago1 in 
Foxg1-RNAa.
To further explore mechanisms leading to RNAa, we monitored the enrichment of the Foxg1 locus for 
RNApolII, upon saRNA delivery to neural precursors. We found that both miR-α Foxg1.0650 and 0.1694 robustly 
increased RNApolII recruitment along the entire locus (Figs 4A,F,G and Supplementary Table 2), which likely 
led to augmented transcription rates. Intriguingly, the absolute RNApolII recruitment profile did not display any 
sudden decrease downstrem of Foxg1-TSS in control conditions (Fig. 4A and S3, and Supplementary Table 2). 
Moreover, no abrupt increase of RNApolII recruitment took place in the same position upon saRNA delivery 
(Fig. 4A,F,G, and Supplementary Table 2). Altogether these data suggest that RNApolII does not normally pause 
near Foxg1-TSS and saRNAs stimulate Foxg1 transcription by promoting RNApolII recruitment to TSS.
In vivo Foxg1-RNAa. Although highly flexible and powerful for analytical purposes, lentiviral vectors 
employed throughout this study would pose obvious concerns for in vivo exploitation, due to their insertional 
mutagenesis activity. In principle, we could circumvent this issue replacing lentivirus-encoded saRNAs by their 
synthetic siRNA-like analogues. To preliminarily explore this possibility, we delivered siRNA-α Foxg1.1694 
(a synthetic analogue of miR-α Foxg1.1694) or the siRNA-α GFP control to murine neocortical differentiating 
derivatives, by Lipofectamine-RNAimax transfectant. Interestingly, siRNA-α Foxg1.1694 specifically upregu-
lated Foxg1-mRNA, by 1.47 ± 0.02-folds (Fig. S4A,B and Supplementary Table 2). Encouraged by this result, we 
repeated this in vitro assay, replacing the commercial transfectant by the Chimeric Rabies Virus Glycoprotein 
Fragment (RVG-R9). This polypeptide may be easily loaded with nucleic acids, it crosses the blood-brain-barrier 
(BBB) and targets the vast majority of CNS cells via a specific interaction with the α 7 chain of the nicotinic 
receptor51. As such, it is a promising tool for therapeutic brain targeting. Interestingly, RVG-R9-mediated 
Figure 2. Histogenetic outcome of Foxg1-RNAa. (A,B) Protocols and lentiviral reagents employed for 
this assay. (C) Quantification of cells immunopositive for the neuron-specific Tubβ 3 marker, in cultures of 
neocortical precursors expressing Foxg1-saRNAs. (D) Examples of Tubβ 3+ immuno-fluorescences referred to 
in (C). E, embryonic day. DIV, days in vitro. Bars represent sem’s. n = number of biological replicates. Statistical 
significance of results evaluated by t-Student assay (one-tail, unpaired). Absolute average frequency of Tubβ 3+ 
cells in NC samples was (27.25 ± 0.16)%.
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siRNA-α Foxg1.1694 transfection replicated Foxg1-mRNA upregulation obtained by RNAimax (Fig. S4C,D and 
Supplementary Table 2). Given the documented expression of α 7 in proliferating neocortical precursors52, we 
tested if the RVG-R9/siRNA-α Foxg1.1694 complex might upregulate Foxg1 even in neurospheres originating 
from E12.5 cortical tissue. Unfortunately, the huge upregulation detected (almost 9-folds) was not specific, since 
it was also achieved by the RVG-R9/siRNA-α GFP control complex (Fig. S4E,F and Supplementary Table 2). Even 
worse, such upregulation was associated to massive differentiation of proliferating precursors to postmitotic neu-
rons (Fig. S4G). Therefore, in vivo employment of RVG-R9 might lead to a detrimental precocious exhaustion of 
neuronogenic niches. Because of that, we considered an alternative delivery tool for our saRNAs.
We chose to administer miR-α  Foxg1.1694 to the living brain through AAV9-pseudotyped, 
self-complementary AAV2-derivative, adeno-associated viral vectors, under the control of a constitutive pro-
moter (Fig. 5A). We injected 3*1010 infecting particles into the right lateral ventricle of P0 mouse pups by free 
hands. We sacrificed these animals three weeks later (P21) and scored their right neocortices for Foxg1-mRNA 
content as well as for the frequency at which Foxg1+ cells were AAV-transduced (Fig. 5B,C). Remarkably, Foxg1 
was upregulated by 1.66 ± 0.30 folds (Fig. 5D and Supplementary Table 2), even though the transduction fre-
quency of Foxg1+ cells was only 0.17 ± 0.01 (Fig. 5E,F).
Figure 3. Compliance of Foxg1-RNAa with endogenous gene regulation. (A) Idealized representation of the 
murine early neural tube, including cortical (cx), mesencephalic (me) and rhombo-cervical (rh/c) domains. (B) 
Protocols and lentiviral reagent employed for the assay referred to in (C). (C) Impact of miR-α Foxg1.0650 and 
0.1694 on Foxg1-mRNA levels in proliferating precursors from the me/rh/c and cx domains. (D) Protocols and 
lentiviral reagent employed for the assay referred to in (E). (E) Foxg1-mRNA modulation by miR-α Foxg1.1694 
in differentiating neocortical derivatives upon their timed terminal exposure to 25 mM K+. E, embryonic 
day. DIV, days in vitro. Bars represent sem’s. n = number of biological replicates. Statistical significance of 
results evaluated by t-Student (one-tail, unpaired) (C) and ANCOVA (two-ways, unpaired) (E) assays. ns, not 
significant.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:39311 | DOI: 10.1038/srep39311
Figure 4. Molecular mechanisms underlying Foxg1-RNAa. (A) Schematics of the Foxg1 locus including 
miRNA and gapmer positions and orientations, as well as diagnostic qPCR amplicons. (B) AK158887-ncRNA 
and Foxg1-mRNA levels in NIH/3T3 cells upon combined delivery of miR-α Foxg1.0650 and gapmer-α 
AK158887-1.1. Values double normalized, against Gapdh and control (NC). (C,D) qPCR quantification of 
Foxg1 chromatin enrichment, upon immunoprecipitation (ChIP) by antibodies against Argonaute 2 (α -Ago2) 
and Argonaute 1 (α -Ago1). Evaluation performed in neocortical precursors challenged by miR-α Foxg1.0650 
(C) and miR-aFoxg1.1694 (D), according to the protocol shown in Fig. 1B,C. Values double normalized 
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Discussion
Active in telencephalic precursors and their postmitotic derivatives, the brain patterning gene Foxg1 controls a 
variety of neurodevelopmental and physiological processes. Its allele dosage is crucial, since its duplication and 
deletion result in West and Rett-like syndromes, respectively. As a proof-of-principle of RNAa therapy of Foxg1 
haploinsufficiency, here we selected 8 artificial saRNAs upregulating Foxg1 in neocortical precursors, 1 of which 
worked in their postmitotic derivatives too (Fig. 1). Expression of these saRNAs elicited an appreciable biological 
outcome (Fig. 2). RNAa was restricted to neural cells expressing the target gene and did not interfere with its 
endogenous tuning (Fig. 3). saRNAs recognized their target chromatin through nascent ncRNAs and recruited 
RNApolII to it, possibly via Ago1 (Fig. 4). Finally, delivery of one saRNA to mouse neonates, by intraventricular 
injection of recombinant AAV vectors, replicated Foxg1-RNAa in vivo (Fig. 5).
Interestingly, only one out of the best four miRNAs activating Foxg1 in proliferating neocortical precursors 
worked satisfactorily in their postmitotic derivatives (Fig. 1A,E,F). This may be due to the different epigenetic 
state of chromatin, generally more accessible in the former ones53,54. It may specifically reflect a different ncRNA 
landscape at the Foxg1 locus. Despite the moderate amplitude of Foxg1-upregulation achieved by RNAa, such 
manipulation elicited a pronounced histogenetic effect (Fig. 2). This was not a surprise. A high sensitivity of neu-
ronogenic rates to even subtle changes of Foxg1 levels was already reported29. Moreover, similar phenomena were 
described for a number of other patterning genes, including Emx2 and Pax645,55,56.
We also found that the saRNAs achieved a relevant molecular outcome only in primary cultures where the 
gene of interest was active (Fig. 3A–C). This suggests that therapeutic saRNA delivery, driven by a ubiquitous 
promoter or achieved via straight administration of pre-made, synthetic molecules, should be followed by the 
activation of the target gene limited to its standard expression domain. Moreover, within responsive neurons, 
saRNAs elicited a gentle and reproducible stimulation of the gene in order, which did not interfere with its fine 
endogenous tuning (Fig. 3D,E). All that strenghtens the saRNA suitability for precise and affordable treatment of 
haploinsufficiences, with special emphasis on those of neurological interest.
Concerning mechanisms of RNAa, the employment of gapmers against ncRNAs stemming from the target 
locus is an elegant method for unveiling its molecular logic. Specifically, if the gapmer reproduces the saRNA 
effect, then gene activation should originate from destabilization of its ncRNA target, as described for Bdnf by ref. 
57. If the gapmer suppresses saRNA activity - as reported for PR and COX2 by refs 38 and 50 - then RNAa should 
rather rely on the recruitment of transactivating effectors to the target locus, via ncRNA docks stemming from it. 
The latter scenario is what we observed for Foxg1 upon delivery of miR-α Foxg1.0650 (Fig. 4B). Other antisense 
saRNAs stimulating this gene might work in a similar way. Sense-oriented saRNAs might land on not yet mapped, 
Foxg1-associated antisense-ncRNAs, or act according to a different molecular logic.
Beyond target chromatin recognition by saRNAs, a crucial role in RNAa is played by Argonautes, which act as 
adaptors between the chromatin-bound saRNAs and the effector complex stimulating transcription. In a number 
of cases, Ago2 was reported to be the key player. It binds the target gene through saRNAs, it mediates the assem-
bly of a supramolecular dock for RNApolII, and it is ultimately necessary for RNAa35,50,58–60. Ago1 binds to TSS 
surroundings too. Moreover, it interacts with RNApolII and is involved in transcription regulation49. However, 
initial reports implicated it in transcriptional gene silencing (TGS) rather than RNAa35,58. Unexpectedly, we found 
that suppressing Ago1 by morpholino abolished Foxg1-RNAa (Fig. 4E). This phenomenon is consistent with 
the recruitment of Ago1 to the Foxg1 promoter, triggered by saRNAs (Fig. 4D). It echoes the recent report of 
Ago1-dependent RNAa at the IL2 locus61.
A step further along the RNAa cascade, RNApolII is recruited to TSS49,58,59,62–64 or possibly stimulated to 
progress downstream of it65. In case of Foxg1-mRNA, the RNApolII enrichement profile of the gene, in baseline 
conditions as well as upon miR-α Foxg1.0650 and .1694 delivery (Figs S3 and 4F,G), suggests that the former 
mechanism applies.
miR-α Foxg1.1694 worked also in vivo (Fig. 5). Here, the cumulative Foxg1 expression gain was about + 68%, 
albeit only 1/6 of Foxg1-expressing cells were targeted. This means that the actual expression gain in targeted 
Foxg1+ cells might be not far from 6*68%, i.e. about + 400%. This suggests that, in a therapeutic scenario, saRNA 
expression should be dampened to restore physiological Foxg1-mRNA expression levels, possibly via a weaker 
promoter or a tunable transactivating system. Moreover, the employment of more advanced AAV drivers66 might 
help targeting the almost totality of telencephalic neural cells.
In summary, we have selected a set of artificial miRNA eliciting a gentle Foxg1 transactivation, specifically in 
cortico-cerebral cells. Their delivery led to an appreciable biological outcome, while complying with endogenous 
gene tuning. They stimulated RNApolII recruitment, possibly via Ago1. One of these miRNAs worked prom-
isingly in vivo, even though its therapeutic employment still requires further optimization. As recently shown, 
hemizygosity for specific genes and polygenic chromosomal segments underlies a huge number of neuropatho-
logical entitites1–5, for which no cure are presently available. Based on results reported above, RNAa might be a 
simple and scalable approach for fixing this class of problems.
against input chromatin and control (NC). (E) Foxg1-mRNA levels in NIH/3T3 cells upon combined delivery 
of miR-α Foxg1.1694 and morpholino-α Ago1. Values double normalized, against Gapdh and control (NC). 
(F,G) qPCR quantification of Foxg1 chromatin enrichment, upon ChIP by antibodies against RNA polymerase 
II (α -RNA-polII). Evaluation performed in neocortical precursors challenged by miR-α Foxg1.0650 (F) and 
miR-aFoxg1.1694 (G), according to the protocol shown in Fig. 1B,C. Values double normalized against input 
chromatin and control (NC). Bars represent sem’s. n = number of biological replicates. p-values were calculated 
by the t-Student algoritm (one-tail, unpaired). All panel 4 F results with p < 0.05 further passed Benjamini-
Hochberg filtering, with FDR < 1 /m. The same applies to panel 4 G, except amplicon6 results.
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Materials and Methods
Animal handling. Wild-type, CD1 strain mice used in this study were purchased from Envigo-Italy and 
housed at the SISSA mouse facility. Animals handling and subsequent procedures were in accordance with 
European [European Communities Council Directive of November 24, 1986 (86/609/EEC)] and Italian laws 
(D.L. 04.03.2014, n°26) and were approved by SISSA Board for Animal Welfare. Embryos were staged by timed 
breeding and vaginal plug inspection. Neonates were staged as “P0” on their birthday.
Figure 5. Foxg1-RNAa in murine neocortex. (A) Schematics of AAV9-pseudotyped, self-complementary 
AAV2-derivative, adeno-associated viral vector, driving constitutive expression of Foxg1-activating miRNAs. 
(B) Protocol employed for the assays referred to in (C–F). (C) Location of neocortical sectors subject of the 
analyses shown in (D–F). (D) Quantification of Foxg1-mRNA levels in neocortex of juvenile mice previously 
injected by scAAVs encoding for miR-α Foxg1.1694. (E) Evaluation of frequency of Foxg1+ cells transduced 
by EGFP-encoding control virus (NC). (F) Examples of α Foxg1/α EGFP-immunoprofiled sections referred 
to in (C,E). P, post-natal day. Bars represent sem’s. n = number of biological replicates (i.e. brains). Statistical 
significance of results evaluated by t-Student assay (one-tail, unpaired).
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Cell cultures. Embryo harvesting. Embryos (E10.5, E12.5 and E16.5) were harvested from pregnant dams 
killed by cervical dislocation and put in sterile ice-cold PBS supplemented with 0.6% glucose. Cerebral cortices 
(E12.5 and E16.5), mesencephalons (E10.5) and rhombocervical tracts (E10.5) were then dissected and collected 
in the same solution.
Primary cells. E12.5 cerebral cortices as well as E10.5 mesencephalons and rhombo-cervical tracts were 
mechanically dissociated to single cells by gentle pipetting. Neural precursor cells were subsequently counted 
in a Burker chamber and plated in 24-multiwell plates (Falcon), at the density of 1,000 cells/μ l, in prolifera-
tive medium [DMEM-F12 (Gibco), 1X Glutamax (Gibco), 1X N2 (Invitrogen), 1 mg/ml BSA, 0.6% glucose, 
2 μ g/ml heparin (Stem Cell Technologies), 20 ng/ml bFGF (Invitrogen), 20 ng/ml EGF (Invitrogen), 1X Pen- 
Strept (Gibco), 10 pg/ml Fungizone (Gibco)]. Neural precursors were acutely infected by recombinant lentivi-
ruses and kept in culture up to 96 h. Multiplicities of infection (moi’s) are reported in the corresponding figures.
Cortical tissue from E16.5 mice was chopped to small pieces for 5 minutes, in the smallest volume of ice-cold 
1X PBS-0,6% glucose-1 mg/ml DNaseI. The minced tissue was then resuspended and digested in 0.25 mg/ml 
trypsin-1mg/ml DNAseI for 5 minutes at 37 °C. Digestion was stopped by adding ≥ 1.5 volumes of DMEM/
F12/10%FBS. Cortical tissue was spinned down and transferred to differentiative medium. The suspension was 
pipetted 5–8 times with a P1000 Gilson pipette and undissociated tissue was left to sediment for 1–2 minutes. The 
supernatant was harvested and the living cells counted. 1 × 10^6 cells/well were plated on poly-L-Lysine coated 
12 multiwell plates, in 600 μ l of differentiative medium [Neurobasal-A (Gibco), 1X Glutamax (Gibco), 1X B27 
supplement (Invitrogen), 25 μ M L-glutamate, 25 μ M β -Mercaptoethanol (Gibco), 2% FBS, 1X Pen/Strept (Gibco), 
10 pg/ml Fungizone (Gibco)]. Dissociated neural cells were infected 24 hours later and kept in culture up to 7 
days. Multiplicities of infection (moi’s) are reported in the corresponding figures. When required, doxycycline 
was added to the culture medium, at 2 μ g/ml. Medium was half-replaced with fresh one every 3.5 days.
HEK293T and NIH/3T3 cells. Cells were cultured in DMEM-GlutamaxTM (Gibco)-10% FBS, at 125,000 and 
25,000 cells/cm2, respectively, according to standard protocols. Lentiviral transductions were performed at moi’s 
reported in the corresponding figures. When appropriate, α Ago1 and α GFP morpholinos (GeneTools) were 
delivered to NIH/3T3 cells at 10 μ M, by 6 μ M EndoPorterTM carrier (GeneTools), according to manufacturer’s 
instructions. When appropriate, α AK158887-1.1 or control Antisense LNA GapmeRs (Exiqon) were delivered to 
cells at 50 nM, by Lipofectamine 3000 reagent (TermoFisher), according to manufacturer’s instructions.
Selection of candidate saRNAs. cDNAs encoding for pri-miRNAs targeting the Foxg1 locus were 
designed using “BLOCK-iT™ RNAi Designer” (Invitrogen). This is a proprietary, freely online accessible pro-
gram, conceived for selection of pri-miRNA-155-based, artificial miRNAs to be employed for gene knock-down. 
We repurposed it for designing potential small miRNA-like activators of Foxg1 expression. The 4kb genomic 
region extending from − 3.8 kb to + 0.2 kb with respect to the 5′ Foxg1-mRNA TSS (Fig. 1A) was scanned in 
0.5kb frames, in both sense and antisense orientation. Candidate miRNAs with a score ≥ 4.5/5 were shortlisted. 
They were further filtered for absence of potential off-targets within the murine genome and transcriptome, by 
Blat (UCSC) and Blastn (NCBI) softwares, respectively. A subset of them, recognizing targets evenly distributed 
within the 4.0 kb reference region and including hits with different homologies to their human counterparts, was 
selected. A summary of these candidate miRNAs and their key parameters is provided in Supplementary Table 1.
Lentiviral vector construction. cDNAs encoding for pri-miRNAs targeting the Foxg1 locus were 
designed using “BLOCK-iT™ RNAi Designer” (Invitrogen). Genomic locations of their targets are listed 
in Supplementary Table 1. The negative control pri-miRNA-cDNA derived from “pcDNATM-6.2-GW/
EmGFP-miR_neg_control_plasmid” (Invitrogen), as described in ref. 45. These pri-miRNA-cDNAs were cloned 
into BfuAI-digested pLVmiR.2345, so obtaining “LTR-pPgk1-eGFP-pri-miR-Wpre-LTR” constitutive expressors 
[Fig. 1(a)]. The TetON-controlled “LTR-TREt-eGFP-pri-miR-Wpre-LTR” pri-miRNA expressors [Fig. 1B(b2)] 
were obtained by transferring the AgeI/KpnI inserts originating from the corresponding constitutive expressors 
into AgeI/KpnI cut LV:TREt-IRES2-EGFP67. Finally, “LTR-pPgk1-rtTAM2-Wpre-LTR” [Fig. 1B(b1)] was described 
in ref. 68. For each construct, inserts and their surroundings were checked by double strand sequencing.
Recombinant lentivirus production. Recombinant third generation self-inactivating (SIN) lentiviruses 
were produced and titrated as previously described68.
RNA profiling. Total RNA was extracted from cells using TRIzol Reagent (Invitrogen) according to manu-
facturer’s instructions. Agarose gel electrophoresis and spectrophotometric measurements (NanoDrop ND-1000) 
were employed to estimate its concentration, quality and purity. RNA preparations were treated by TurboDNAseI 
kit (Gibco) 1 h at 37 °C. At least 0.5 μ g of total RNA from each sample was retrotranscribed by SuperScriptIIITM 
(Invitrogen) in the presence of random hexamers, according to the manufacturer’s instructions. 1/100 of the 
resulting cDNA was used as substrate of any subsequent qPCR reaction. Next, negative control PCRs were 
run on RT− cDNA preparations. In general, PCR reactions were performed by the SsoAdvanced SYBR Green 
SupermixTM platform (Biorad), according to manufacturer’s instructions. For each transcript under examination 
and each sample, cDNA was PCR-analyzed in technical triplicate, against absolute standards, and average results 
calculated. Averages were normalized against Gapdh and further normalized against controls. Experiments were 
performed at least in biological triplicate and analyzed by Student’s t-test.
Western Blotting. Western analysis was performed according to standard methods. Total cell lysates in 
CHAPS buffer were quantified by BCA protein assay kit (Fisher Scientific #10678484) and denatured at 95 °C for 
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5 min, prior to loading. Twenty-five micrograms of proteins were loaded per each lane of a 12% acrylamide− 0.1% 
SDS gel. FOXG1/Foxg1 was detected by a primary rabbit anti- Foxg1 polyclonal antibody41, used at 1:2000, and a 
secondary HRP-conjugated anti-rabbit antibody (LifeTech #32260), used at 1:2000. β ACT was detected by a per-
oxydase C-conjugated mouse monoclonal antibody (Sigma #A3854), used at 1:10 000. FOXG1/Foxg1 and β ACT 
were sequentially revealed by an ECL kit (GE Healthcare # GERPN2109). Images were acquired by an Alliance 
LD2–77.WL apparatus (Uvitec, Cambridge) and analyzed by Adobe Photoshop CS2 softwareTM and Microsoft 
Excel 11 softwareTM.
ChIP-qPCR. The chromatin immunoprecipitation quantitative polymerase chain reaction assays 
(ChIP-qPCRs) were performed on chromatin extracted from neural cell cultures. Cells were acutely infected 
with bio-active and control lentiviruses. Then, they were kept in culture for 96 h. ChIP analysis was performed 
according to the MAGnifyTM Chromatin Immunoprecipitation System protocol (Invitrogen), with minor mod-
ifications. For each ChIP assay, chromatin from 106 cells was fixed by 1% formaldehyde, for 10 min at RT. After 
cell lysis, fixed chromatin was sonicated by a Soniprep 150 apparatus into ~600 bp fragments (on ice; 5 s ON, 55 s 
OFF; oscillation amplitude 5 μ m; 4 cycles). Sonicated chromatin was immunoprecipitated for 2 h at 4 °C, by 2.5 μ 
g of an anti-RNApolII antibody (mouse clone 4H8, Abcam #ab5408), 2.5 μ g of an anti-Ago1 (mouse clone 6D8.2, 
Millipore #04–083), 3.0 μ g of an anti-Ago2 (rabbit polyclonal, Abcam #32381) or 2.5 μ g of murine IgG (from 
MAGnify kit, Invitrogen), in a final volume of 100 μ l. Immunoprecipitated DNA was purified according to the 
manufacturer’s instructions. Lastly, 1/60 of each immunoprecipitated (IP) DNA sample was amplified by qPCR. 
For each sample, qPCRs were performed in technical triplicate. Averages were normalized against input chroma-
tin and further normalized against control-treated samples. Experiments were performed at least in biological 
triplicate and analyzed by Student’s t-test.
siRNA-RNAiMAX transfection. Sequences of siRNAs targeting the Foxg1 locus and their anti-GFP con-
trol are provided in Supplementary Table 1. For transfection, E16.5 mouse post-mitotic neurons were seeded in 
12-well plates at about 3 × 10^5 cells/well in 600 μ l Neurobasal A-based differentiative medium. At the same time 
of seeding, 15 pmol of each siRNA was complexed with 2 μ l of Lipofectamine RNAiMAX reagent (Invitrogen) 
and transfected to the cells to a final 25 nM concentration, according to the manufacturer’s protocol. 24 h after 
transfection, medium was replaced and siRNAs were re-transfected as described above. RNA was extracted 48 h 
after the second transfection and analyzed by qRTPCR.
siRNA-RVG-9dR transfection. The sequence of RVG-9dR peptide (synthesized by LifeTein) is reported in 
Supplementary Table 1. For RVG-9dR-mediated transfection, the different siRNA duplexes (100 pmol each) were 
incubated with RVG-9R peptide at a 1:10 molar ratio in 15 μ l, for 15 min at room temperature. RNA-polypeptide 
binding was assessed on not-denaturing agarose gel by electrophoretic mobility shift assay. Next, the complexes 
were added to acutely dissociated E12.5 or E16.5 neural cells, plated in 24-well plates, at 1,5 × 10^5 cells/300 μ l, or 
in 12-well plates, at 3 × 10^5 cells/600 μ l, respectively. 24 h later, the transfection was repeated as described above. 
Cells were cultured for further 48h and, finally, RNA was extracted and examined by qRTPCR.
Adeno-associated virus cloning and production. As for AAV production, genomic plasmids were 
obtained by transferring “Pgk1p-EGFP-pri-miRNA” modules from the corresponding lentiviral expressors into 
a scAAV2-type backbone [AAVscCB6(p1023)Q], upstream of a rabbit-polyA signal. Recombinant AAVs were 
packaged as previously described69.
In vivo RNAa assays. P0 pups were anaesthetized on ice for 40–60 s. 3*1010 AAVs particles, mixed with 
0.02% fast-green dye, were injected through the skull into the lateral ventricle, by free hands, using a sharp pulled 
micropipette (hole external diameter about 40 μ m) with the help of light fibers. Animals were left to recover in 
a warm clean cage. Next they were transferred to their mother. 21 days later they were finally sacrificed. Brains 
were dissected from the skull, neocortices were homogenized and resuspended in TRIzol reagent (Ambion). 
Alternatively, for immunofluorescence, brains were fixed in fresh 4% PFA overnight at 4 °C. Next, they were cryo-
protected overnight in 30% sucrose-1X PBS at 4 °C and finally frozen on dry ice in Killik (BioSigma).
Immunofluorescence. Lentivirus transduced, floating neural precursor aggregates were gently trypsinized 
to single cells and left to attach 1 h at 37 °C to poly-L-lysine (200 μ g/ml) coated SuperFrost Plus microscope slides 
(Menzel-Glaser). Here they were fixed by 4% PFA for 20 min at 4 °C, washed three times in 1X PBS and processed 
for immunofluorescence. Fixed-cryopreserved brains were sliced at 16 μ m, tissue slices were allowed to dry at 
least one hour at RT and processed for immunofluorescence.
In all cases, immunofluorescence was performed as previously described45. The following primary antibodies 
were used: anti-Tubb3 (mouse clone Tuj1, Covance #MMS-435P, 1:1000); anti-GFP (chicken polyclonal, Abcam 
ab13970, 1:400); anti-Foxg1 (rabbit polyclonal, 1:20041). Secondary antibodies were conjugates of Alexa Fluor 488 
and 594 (Invitrogen), used at 1:600. Cell nuclei were counterstained with DAPI (4′ , 6′ -diamidino-2-phenylindole).
Tubb3 immunofluorescences were photographed on a Nikon Eclipse TS100 fluorescence microscope 
equipped with a DS-2MBWC digital microscope camera with a 20X objective. Immunoprofiled brain sections 
were photographed on a Nikon TI-E microscope, equipped with 20X or 40X objectives and a Hamamatsu C4742–
95 camera. All images were processed using Adobe 9.0.2 Photoshop 2 CS2 software and ImageJ.
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Statistical analysis. As for in vitro assays, each “biological replicate” included cells pooled from at least two 
independent wells/petri dishes. As for in vivo tests, each “biological replicate” corresponded to a single brain. 
Numbers of biological replicates analyzed in each experiment (n) are shown under the corresponding graphs. 
Each biological replicate was scored at least in technical triplicate.
Data were normalized as reported in figure legends and averaged. Variability was graphically shown by stand-
ard error of mean bars.
Statistical significance of results was evaluated by Student’s t-test (unpaired, one-tail) or ANCOVA. In case of 
multiple comparisons (Figs 1E,F and 4F,G), to make each dataset suitable for drawing reliable conclusions from its 
comprehensive evaluation, statistical results were further filtered by the Benjamini and Hochberg algorithm70. In 
such cases, the false discovery rate (FDR) was placed at < 1/m, where m is the multiplicity of the comparison-set. 
Results of Benjamini and Hochberg filtering were summarized in Supplementary Table 2, panel 1E, 1F, 4F and 
4 G datasets.
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